Unicycive Therapeutics (UNCY) Invested Capital (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Invested Capital data on file, last reported at $37.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 234.52% year-over-year to $37.7 million; the trailing twelve-month figure through Mar 2026 stood at $37.7 million (up 234.52% YoY), and the FY2025 full-year result was $30.2 million, up 306.37% from the prior year.
• Invested Capital for Q1 2026 stood at $37.7 million, up from $30.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $10.1 billion in Q2 2023 and bottomed at -$27.8 million in Q3 2024.
• The 5-year median for Invested Capital is $7.4 million (2024), against an average of $597.6 million.
• The widest annual swing landed in 2023, when Invested Capital surged 101551.14%; it then tumbled 911.01% in 2024.
• A 5-year view of Invested Capital shows it stood at -$466000.0 in 2022, then sank by 717.38% to -$3.8 million in 2023, then surged by 295.09% to $7.4 million in 2024, then jumped by 306.37% to $30.2 million in 2025, then grew by 24.86% to $37.7 million in 2026.
• The last three Invested Capital figures came in at $37.7 million (Q1 2026), $30.2 million (Q4 2025), and $37.5 million (Q3 2025), per Business Quant data.

Peer Comparison